glp-1 select trial Clinical efficacy results from clinical trials comparing different CMS Issues Coverage Guidance on

[1] It is not approved for treating type 2 diabetes, though its active ingredient tirzepatide is marketed separately as Mounjaro for that indication

According to studies, the reduced incretin effect in patients with T2DM may be due to a decrease in the response of -cell to GIP and/or GLP-1 or a decrease in GLP secretion [15, 18, 27, 28]

But not everyone has healthy glutathione levels these can drop due to a poor diet, stress, advancing age, and environmental toxins

Understanding whether these medications directly cause tiredness, the contributing factors, and effective management strategies is essential for patients and healthcare providers

Patients can remain on these medications indefinitely, and the clinical data supporting long-term use extends to multiple years